Gray Zone-What to do with Deauville 3 interim PET/CT response in a young woman with classical unfavorable Hodgkin's Lymphoma - To irradiate or not to irradiate?
The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics. But despite our best efforts, evidence-based medicine cannot provide 1 clear answer to every clinical problem. In many patient scenarios, the best management approach remains uncertain, leaving room for difference of opinion and constructive debate. To this end, we present the Red Journal Gray Zone where we provide difficult or controversial clinical cases. After each case you will read the management plan favored by a few specialists in that particular field. We also want to hear from you! After reading the case please access the poll and tell us what you think.
Please read "What to do with Deauville 3 interim PET/CT response in a young woman with classical unfavorable Hodgkin's Lymphoma - To irradiate or not to irradiate?", tell us what you think and take the poll.
This activity is available from December 11, 2019 through 11:59p.m. Eastern time on December 10, 2020.
This activity is designed to meet the interest of radiation oncologists and radiation oncology residents.
- Summarize and discuss the management of difficult cases in practice.
Steve Braunstein, MD, PhD (Gray Zone Editor) is employed by University of California, San Francisco and receives compensation/remuneration/funding from Radiation Oncology Questions, LLC.
Anthony Zietman, MD, FASTRO (Editor-in-Chief) is employed by Massachusetts General Hospital and Elsevier, receives compensation/remuneration/funding from the National Cancer Institute (NCI) and holds leadership positions at ABR and NCI.
John Austin Vargo, MD
Mark K. Farrugia, MD, PhD
Richard Hoppe, MD
Joanna C. Yang, MD, MPH
Joachim Yahalom, MD
Bouthaina Shbib Dabaja, MD
Bradford Hoppe, MD, MPH
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is a member only benefit. To become an ASTRO member please go to www.ASTRO.org and click “Join ASTRO”.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 1 year period regardless of purchase date. At the expiration of the qualification date, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.